HeraMED EBITDA TCAC 5A

Que fait HeraMED ? HeraMED Ltd. generates revenue through the sale of hardware solutions and related software applications. Its flagship product, HeraBEAT, is a medical-grade, clinically-validated connected Ultrasound Fetal Doppler device designed for expectant mothers to self-monitor their fetus' heart rate at home. The device connects via Bluetooth Low Energy to smartphones, transmitting data to a dedicated app that displays readings. The company also offers a homecare pregnancy solution service, leveraging AI and machine-learning algorithms to analyze fetal data and provide insights to healthcare professionals or home users. Sales are primarily directed to expectant mothers seeking home monitoring tools and healthcare providers integrating these solutions into patient care. HeraBEAT is marketed as a clinically-validated tool for home use, distinguishing it from standard consumer devices. The product’s integration with smartphone applications enables real-time data access, appealing to tech-savvy parents. The homecare pregnancy solution complements the hardware by offering ongoing support through AI-driven analysis, enhancing user engagement and retention. Healthcare professionals benefit from the data insights provided, potentially incorporating HeraBEAT into routine prenatal care protocols. The company’s revenue streams are built around direct sales of HeraBEAT devices and subscription-based services tied to the homecare solution. Expectant mothers purchase the hardware and access the software interface, while healthcare providers may adopt the service model for patient monitoring. AI and machine-learning capabilities are embedded in the product offering, positioning HeraMED as a provider of both medical devices and data-driven health services. HeraMED est l'une des entreprises les plus populaires sur Eulerpool.